Evaluating safety in patients with leukemia or lymphoma treated with mogamulizumab after stem cell transplantation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort study aims to assess non-relapse mortality and toxicities in patients with cutaneous T cell lymphoma (CTCL) or adult T cell leukemia/lymphoma (ATLL) who have been treated with mogamulizumab around the time of allogeneic hematopoietic stem cell transplantation (alloHCT). Participants will be followed for data collection at various time points, including baseline, 100 days, 6 months, 1 year, and 2 years post-transplant. The study will include both retrospective and prospective data collection to evaluate the safety profile of mogamulizumab in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients registered to the Center for International Blood and Marrow Transplant Research (CIBMTR)
* Adults ≥18 years of age with either CTCL or ATLL;
* AlloHCT performed from January 2012 onward.

Exclusion Criteria:

• Patients without consent for research.

Where it's running

• Cibmtr
  Milwaukee, Wisconsin, United States Recruiting

Study contacts

• Study coordinator: Linda J Burns, MD
• Email: lburns@mcw.edu
• Phone: 414-805-0714

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining pembrolizumab and mogamulizumab for advanced cutaneous T-cell lymphomas

  This study is testing if combining two drugs, pembrolizumab and mogamulizumab, can help people with advanced cutaneous T-cell lymphomas that haven't responded to other treatments.

  Recruiting Phase 2 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT05956041

• Ruxolitinib maintenance after stem cell transplant for T‑cell lymphoma

  This phase II trial tests whether taking ruxolitinib after a stem cell transplant can lower the chance of relapse and graft‑versus‑host disease for people treated for T‑cell lymphoma.

  Recruiting at 2 sites Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio and 1 other locations · NCT07356245

• Poteligeo (mogamulizumab) for adults with mycosis fungoides or Sézary syndrome

  This project will try Poteligeo (mogamulizumab) in adults with mycosis fungoides or Sézary syndrome who have had at least one prior systemic therapy to see how safe and effective it is in routine care in Korea.

  Recruiting at 5 sites Kyowa Kirin Co., Ltd. · Busan, Busan Metropolitan City and 5 other locations · NCT07132567

• Ropeginterferon treatment for cutaneous T‑cell lymphoma

  This trial tests whether ropeginterferon-alfa-2b helps people with cutaneous T‑cell lymphoma who have not responded adequately to multiple prior skin-directed therapies.

  Recruiting Phase 1 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07047885

• Mogamulizumab-associated rash in people with mycosis fungoides or Sézary syndrome

  See if a rash that appears while taking mogamulizumab is a drug-related rash and how it links to treatment response in adults with relapsed or refractory mycosis fungoides or Sézary syndrome.

  Recruiting at 2 sites City of Hope Medical Center · Duarte, California and 9 other locations · NCT07003100

• Personalized exercise and nutrition program to reduce cancer-related fatigue

  This program will try a personalized exercise and diet plan to reduce fatigue for adults with indolent lymphomas (including CLL/SLL and follicular lymphoma).

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06860880

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.